{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.77","upperLimit":"4.37","value":"2.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Progression free survival is defined as the time from date of registration to the date of disease progression or date of death from any cause. Patients not reaching progression or death at the time of analysis will be censored at the last date they were known to be alive and progression free.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"OG000","title":"Avelumab"}],"paramType":"MEDIAN","populationDescription":"Per-protocol population defined as all patients recruited to the trial who started treatment","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}